Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | REN | P00797 | 18/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137730 | 1.00 | LDHA (0.55) | LDHARENPPARA | |
| SCHEMBL2140294 | 1.00 | LDHA (0.55) | LDHARENPPARA | |
| SCHEMBL14788425 | 0.90 | PPARG (0.49) | RENPPARA | |
| SCHEMBL14778723 | 0.89 | PPARD (0.53) | LDHARENPPARA | |
| SCHEMBL15184372 | 0.89 | REN (0.55) | REN | |
| SCHEMBL14778721 | 0.89 | REN (0.55) | REN | |
| SCHEMBL14777725 | 0.87 | LDHA (0.49) | LDHARENPPARA | |
| SCHEMBL14777723 | 0.87 | REN (0.53) | REN | |
| SCHEMBL4456020 | 0.86 | REN (0.54) | REN | |
| SCHEMBL4456027 | 0.86 | REN (0.54) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | claimed |
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | claimed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| EP-2275398-B1 | APPLICATION OF AN IRIDIUM COMPLEX IN ASYMMETRIC CATALYTIC HYDROGENATION OF AN UNSATURATED CARBOXYLIC ACID | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2016-05-04 | — | — | EP | disclosed |
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| US-8692018-B2 | Application of iridium complexes in asymmetric catalytic hydrogenation of unsaturated carboxylic acids | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2014-04-08 | — | — | US | disclosed |
| US-8692018-B2 | Application of iridium complexes in asymmetric catalytic hydrogenation of unsaturated carboxylic acids | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2014-04-08 | — | — | US | disclosed |
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2013-09-05 | — | — | US | disclosed |
| WO-2006075166-A1 | METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES | PHOENIX CHEMICALS LTD. (GB) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2003103653-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | VRK2, VRK1, LPXN | LDHA 1570/4885REN 113/4885PPARA 2532/4885 |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | LDHA 2203/4885REN 970/4885PPARA 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.